Allworth Financial LP Has $4.75 Million Position in Axon Enterprise, Inc $AXON

Allworth Financial LP grew its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 455.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,734 shares of the biotechnology company’s stock after buying an additional 4,701 shares during the quarter. Allworth Financial LP’s holdings in Axon Enterprise were worth $4,747,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Axon Enterprise by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after acquiring an additional 185,571 shares in the last quarter. Alliancebernstein L.P. grew its stake in Axon Enterprise by 15.9% in the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock valued at $675,812,000 after purchasing an additional 175,890 shares in the last quarter. Westfield Capital Management Co. LP increased its position in shares of Axon Enterprise by 29.8% during the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the last quarter. Northern Trust Corp raised its stake in shares of Axon Enterprise by 1.2% during the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after purchasing an additional 8,794 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Axon Enterprise by 23,203.7% during the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AXON has been the subject of several analyst reports. UBS Group decreased their target price on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research report on Tuesday, August 5th. Bank of America upped their target price on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Finally, JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research note on Thursday, July 17th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $810.71.

Insider Transactions at Axon Enterprise

In other news, President Joshua Isner sold 15,919 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the transaction, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director directly owned 1,416 shares in the company, valued at $1,065,596.64. The trade was a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 49,932 shares of company stock valued at $36,802,716. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Down 2.1%

Shares of NASDAQ AXON opened at $572.18 on Wednesday. The stock’s fifty day moving average is $712.93 and its 200 day moving average is $736.90. The stock has a market capitalization of $45.15 billion, a P/E ratio of 141.28, a PEG ratio of 29.49 and a beta of 1.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million for the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business’s revenue was up 30.6% on a year-over-year basis. During the same period last year, the company posted $1.45 EPS. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.